Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial
- PMID: 33052103
- DOI: 10.1684/ejd.2020.3876
Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial
Abstract
Background: The efficacy and safety of calcipotriol plus betamethasone dipropionate gel for the treatment of scalp psoriasis has previously been demonstrated in a four-week trial in a Chinese population.
Objective: To evaluate the long-term safety and efficacy of two-compound gel in Chinese adult patients with scalp psoriasis.
Materials & methods: A multicentre, prospective, randomized, active-controlled trial was established in which subjects were randomized (at a ratio of 4:1) to receive either two-compound gel once daily or calcipotriol scalp solution twice daily for 28 weeks. Incidence of adverse drug reactions (ADRs) of any type and adverse events (AEs) of concern associated with long-term corticosteroid use on the scalp were evaluated.
Results: A total of 951 subjects were randomly assigned to receive either two-compound gel (n=760) or calcipotriol scalp solution (n=191). The incidence of ADRs was significantly lower in the two-compound gel group compared with the calcipotriol scalp solution group (11.7 vs. 22.2%, p<0.001). There was no significant difference in treatment-emergent adverse events (TEAEs) associated with long-term topical corticosteroid use on the scalp (1.1% vs. 0%, p=0.369) between the two groups. A statistically significant difference in the percentage of visits with treatment success according to the Subject's Global Assessment was observed (p=0.009); more subjects had visits with 100% treatment success (15.2 vs. 6.3%) and fewer subjects had visits with 0% treatment success (23.7 vs. 30.8%) using two-compound gel compared to calcipotriol scalp solution.
Conclusion: The two-compound gel was well tolerated and effective in the long-term management of scalp psoriasis in Chinese patients.
Keywords: Chinese; calcipotriol plus betamethasone dipropionate gel; calcipotriol scalp solution; long-term; safety; scalp psoriasis.
Similar articles
-
Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population.Int J Dermatol. 2016 Jan;55(1):106-13. doi: 10.1111/ijd.12788. Epub 2015 Jun 20. Int J Dermatol. 2016. PMID: 26094549 Clinical Trial.
-
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.Br J Dermatol. 2009 Jul;161(1):159-66. doi: 10.1111/j.1365-2133.2009.09116.x. Epub 2009 Mar 26. Br J Dermatol. 2009. PMID: 19416259 Clinical Trial.
-
Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.J Eur Acad Dermatol Venereol. 2014 May;28 Suppl 2:10-21. doi: 10.1111/jdv.12444. J Eur Acad Dermatol Venereol. 2014. PMID: 24684739
-
Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.Drugs. 2011 Apr 16;71(6):709-30. doi: 10.2165/11207300-000000000-00000. Drugs. 2011. PMID: 21504248 Review.
-
Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.Am J Clin Dermatol. 2011 Dec 1;12(6):421-4. doi: 10.2165/11207670-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21967117 Review.
Cited by
-
Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment.J Clin Med. 2021 Nov 28;10(23):5589. doi: 10.3390/jcm10235589. J Clin Med. 2021. PMID: 34884291 Free PMC article. Review.
-
Psoriasis in People With Skin of Color: An Evidence-Based Update.Int J Dermatol. 2025 Apr;64(4):667-677. doi: 10.1111/ijd.17651. Epub 2025 Jan 31. Int J Dermatol. 2025. PMID: 39887710 Free PMC article. Review.
-
The Brain-Skin Axis in Psoriasis-Psychological, Psychiatric, Hormonal, and Dermatological Aspects.Int J Mol Sci. 2022 Jan 8;23(2):669. doi: 10.3390/ijms23020669. Int J Mol Sci. 2022. PMID: 35054853 Free PMC article. Review.
-
Biologic and Non-Biologic Therapies for Scalp Psoriasis: A Network Meta-analysis of Randomized Controlled Trials.Dermatol Pract Concept. 2025 Apr 1;15(2):4793. doi: 10.5826/dpc.1502a4793. Dermatol Pract Concept. 2025. PMID: 40401874 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical